(NASDAQ: RNAZ) Hits Our Radar Tomorrow with Under 900K Shares Listed in its Float

Any content you receive is for information purposes only. Always conduct your own research.  *Sponsored Here’s Why Market Crux Just Put (NASDAQ: RNAZ) In Focus For Tomorrow Morning—Wednesday, June 3, 2026… Get Our Real-Time Updates Sent Directly To Your Phone. Up To 10X Faster Than Email. Take A Look At RNAZ Before Tomorrow Morning… June 2, 2026 (NASDAQ: RNAZ) Hits Our Radar Tomorrow with Under 900K Shares Listed in its Float Dear Reader, Every so often, a clinical-stage biotechnology company strings together a series of announcements that causes us to stop and take a look. That's exactly what happened with TransCode Therapeutics, Inc. (NASDAQ: RNAZ). Within approximately three months, the company initiated a Phase 2a study for TTX-MC138, announced financing arrangements of up to $20M that management says extend operational runway into late 2027/early 2028, and expanded its pipeline through a worldwide royalty-free license for three oncolytic candidates. At Market Crux, we view those developments as exciting enough to place RNAZ on our radar heading into Wednesday, June 3, 2026. Here's what we're seeing and why we're following the story closely. But keep in mind, RNAZ has less than 900K shares listed as available in its public float. When companies have small floats like this, the potential exists for big moves if demand begins to shift. From a technical standpoint, Barchart data currently shows RNAZ's near-term RSI levels in the 20–30 range — a zone commonly interpreted by technical analysts as “oversold territory.” Over the last week, RNAZ has made an approximate 14% move, from around $5.01 on May 27 to $5.75 on June 1. Between the low public float, recent technical setup, and the company’s cluster of fresh clinical and corporate updates, RNAZ has several elements that have us digging deeper. Now the key question is simple: what exactly is TransCode building, and why has this story started to stand out? What TransCode Is Building TransCode Therapeutics is a Boston-based, clinical-stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. Its lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b (miR-10b) — a unique, well-documented biomarker of metastasis found across multiple cancer types. TTX-MC138 is designed to silence this microRNA, disrupting its role in promoting cancer cell spread and survival. Beyond TTX-MC138, TransCode has assembled a growing portfolio of first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. The company's immuno-oncology approach includes RIG-I immunotherapeutic candidates and, most recently, a trio of oncolytic adeno-vi-rus platforms. The $732B Oncology Backdrop The global oncology market is projected to grow from around $279B in 2026 to over $732B within the next 10 years — a near-tripling driven by the demand for targeted, precision oncology solutions. RNA-based therapeutics and immuno-oncology are two of the fastest-growing verticals within that expansion, and both sit at the core of what RNAZ is building. A New Clinical Chapter TransCode has moved TTX-MC138 into a Phase 2a study focused on patients after curative-intent therapy. On May 27, 2026, TransCode announced the initiation of its Phase 2a clinical trial evaluating TTX-MC138 in patients with ctDNA-positive colorectal cancer following curative-intent therapy. The trial is conducted in collaboration with Quantum Leap Healthcare Collaborative (QLHC) through its PRE-I-SPY clinical trial platform — a leading platform for innovative oncology trials and the program's first expansion into colorectal cancer. The trial is expected to enroll up to 45 patients and is led by Principal Investigator Dr. Paula Pohlmann of MD Anderson Cancer Center. The study has received both FDA IND submission acknowledgment and full Institutional Review Board (IRB) approval, enabling site activation and the commencement of patient enrollment. The focus is on minimal residual disease (MRD) — patients who've completed curative therapy and show no radiographic evidence of disease, but still test positive for circulating tumor DNA, meaning microscopic cancer cells may remain. This is one of the most underserved clinical windows in all of oncology, where early intervention could meaningfully alter long-term outcomes. TTX-MC138 is being positioned precisely here — before overt relapse, while the target cell burden is lowest and the potential for durable response is theoretically highest. Expanding Pipeline In March 2026, TransCode secured an exclusive, worldwide, royalty-free license from Unleash Immuno Oncolytics, gaining rights to three adeno-vi-rus-based oncolytic candidates — UIO-524, UIO-525, and UIO-526. The lead candidate, UIO-524, targets muscle-invasive bladder cancer (MIBC), a high-unmet-need indication characterized by a highly immunosuppressive tumor microenvironment and limited durable treatment options. The deal was structured entirely in equity — no cash deployed — preserving the company's operating capital. In April 2026, the company appointed Dr. Anna Moore, PhD — a TransCode co-founder and globally recognized expert in molecular imaging and RNA-targeted cancer therapeutics — as Chair of its Scientific Advisory Board. Dr. Moore brings a 26-year research career at Massachusetts General Hospital (MGH) and Harvard Medical School to that role. A concurrent research agreement with Michigan State University is structured to support preclinical and translational studies, including evaluation of TTX-MC138 in combination with Seviprotimut-L and standard-of-care therapies. Backing The Pipeline On April 7, 2026, TransCode entered into agreements for up to $20M in flexible financing. Management has stated this arrangement extends the company’s runway into late 2027/early 2028, providing additional flexibility as TransCode advances its Phase 2a clinical program for TTX-MC138 and continues expanding its broader oncology pipeline. For a clinical-stage biotechnology company, access to capital can be an important component of execution, allowing the company to focus on key clinical milestones, ongoing research initiatives, and the continued advancement of its therapeutic candidates. 7 Reasons RNAZ Will Be Topping Our Watchlist Tomorrow Morning—Wednesday, June 3, 2026… 1. Technical Signals: With near-term RSI levels shown in the 20–30 range, RNAZ appears to be sitting in a technical zone often viewed as oversold. 2. Small Float: With less than 900K shares listed as available to the public, RNAZ’s small float could witness the potential for big moves if demand begins to shift. 3. Phase 2a Live: With its Phase 2a clinical trial now initiated, RNAZ has a current clinical milestone that market watchers can track in real time. 4. Extended Runway: After securing up to $20M in flexible financing, RNAZ says its runway now extends into late 2027/early 2028. 5. Scientific Leadership: With Dr. Anna Moore appointed Chair of the Scientific Advisory Board, RNAZ added leadership tied to MGH, Harvard Medical School, and RNA-targeted cancer research. 6. Growing Market: RNAZ is operating within the global oncology market, which is projected to expand from approximately $279B in 2026 to more than $732B over the next decade. 7. Pipeline Expansion: Through a worldwide royalty-free license, RNAZ added three oncolytic adeno-vi-rus candidates to its broader oncology pipeline. Take A Look At RNAZ Before Tomorrow Morning… From where we sit at Krypton Street, the convergence of events around RNAZ over the past 90 days is hard to ignore. A Phase 2a trial now actively enrolling at MD Anderson, a balance sheet extended into late 2027/early 2028, a pipeline that now spans RNA silencing and oncolytic immunotherapy, and scientific leadership with elite academic credentials — all while technical indicators suggest the name may be trending in compressed territory. Whether RNAZ becomes a major clinical story will ultimately depend on data, but the operational architecture being assembled here is worth watching closely. Take a look at RNAZ before tomorrow morning. Sincerely, Gary Silver Managing Editor, MarketCrux     MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, MC is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 06/02/2026 and ending on 06/03/2026 to publicly disseminate information about (RNAZ:US) via digital communications. Under this agreement, TD Media LLC has paid Headline Media LLC seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Headline Media LLC has been paid fifteen thousand USD (“Funds”). These Funds were part of the twenty two thousand five hundred USD funds that TD Media LLC received from a third party named Awareness Consulting Network LLC who did not receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Headline Media LLC, TD Media LLC and their member own shares of (RNAZ:US). Please see important disclosure information here: https://marketcrux.com/disclosure/rnaz-ZLnPR/#details

Headline Media | 7901 4th Street N, Suite 300, St. Petersburg, FL 33702 Unsubscribe Update Profile | About our service provider Sent by gary@marketcrux.net